Drugs / RD01
RD01
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03657238 | Apr 2018 → Aug 2019 | — | Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04231292 | Mar → Jun 2020 | anemia | Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04231292 ↗ |
| Known as | PEG-EPO | “single ascending doses of subcutaneous polyethylene glycol-erythropoietin (PEG-EPO) in healthy subjects” PMID 39117488 ↗ Aug 2024 |
| Known as | Pegerythropoietin | “single S.C. doses of RD01 (Pegerythropoietin) in Healthy Chinese Subjects” NCT03657238 ↗ |
| Modality | Protein / enzyme biologic | “polyethylene glycol-erythropoietin (PEG-EPO)” PMID 39117488 ↗ Aug 2024 |
| Route | Subcutaneous | “single ascending doses of subcutaneous polyethylene glycol-erythropoietin (PEG-EPO) in healthy subjects” PMID 39117488 ↗ Aug 2024 |